New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival
August 31 2020 - 09:00AM
Business Wire
- Analysis of combination therapy demonstrated statistically
significant prolongation of survival in a patient-derived xenograft
(PDX) model
- Abstract published online today in
advance of virtual meeting of the Society of Hematologic Oncology
(SOHO) taking place September 9-12, 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced new
preclinical data providing the first evidence that an E-selectin
targeting strategy with uproleselan may help patients with acute
myeloid leukemia (AML) to overcome resistance to venetoclax and
hypomethylating agent (HMA)-based therapy. The poster (Abstract
#AML-337) entitled “Targeting E-selectin with GMI-1271 Overcomes
Microenvironment-mediated Resistance to Venetoclax/HMA Therapy,”
will be presented September 9 from 6:15-8:15 p.m. CDT on the
virtual platform of the virtual meeting of the Society of
Hematologic Oncology (SOHO).
The data presented are from an animal model created using tissue
derived from a patient who had developed resistance to
venetoclax/HMA. In this model, the addition of uproleselan to the
treatment regimen demonstrated robust anti-leukemic activity and a
statistically significant prolongation of survival. The research
strongly supports the opportunity for additional clinical
evaluation of the triple combination of uproleselan, venetoclax and
HMA in the frontline, unfit AML patient population.
“We know that binding leukemic cells to E-selectin within the
bone marrow niche up-regulates pro-survival mechanisms. This
preclinical study shows that by blocking this activity with
uproleselan, we can enhance the sensitivity to venetoclax/HMAs.
This supports using this treatment regimen to potentially improve
outcomes in patients whose duration of response is typically very
short,” said John Magnani, Ph.D., GlycoMimetics’ Senior
Vice-President of Research and Chief Scientific Officer. “We are
excited to share this encouraging data and hope that additional
clinical evaluation will provide more insight on the potential of
this combination-therapy approach.”
Visit the meeting’s website for more information:
https://www.soho2020.com/., The virtual meeting will be held
September 9-12, 2020.
About Uproleselan (GMI-1271)
Discovered and developed by GlycoMimetics, uproleselan is an
investigational, first-in-class, targeted inhibitor of E-selectin.
Uproleselan (yoo’ pro le’ sel an), currently in a comprehensive
Phase 3 development program in AML, has received Breakthrough
Therapy Designation from the U.S. FDA for the treatment of adult
AML patients with relapsed or refractory disease. Uproleselan is
designed to block E-selectin (an adhesion molecule on cells in the
bone marrow) from binding with blood cancer cells as a targeted
approach to disrupting well-established mechanisms of leukemic cell
resistance within the bone marrow microenvironment. In a Phase 1/2
clinical trial, uproleselan was evaluated in both newly diagnosed
elderly and relapsed or refractory patients with AML. In both
populations, patients treated with uproleselan together with
standard chemotherapy achieved better-than-expected remission rates
and overall survival compared to historical controls, which have
been derived from results from third-party clinical trials
evaluating standard chemotherapy, as well as lower-than-expected
induction-related mortality rates. Treatment in these patient
populations was generally well-tolerated, with fewer than expected
adverse effects.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage
clinical development programs and a pipeline of novel glycomimetic
drugs, all designed to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role.
GlycoMimetics' drug candidate, uproleselan, an E-selectin
antagonist, was evaluated in a Phase 1/2 clinical trial as a
potential treatment for AML and is being evaluated across a range
of patient populations including a Company-sponsored Phase 3 trial
in relapsed/refractory AML under breakthrough therapy designation.
Rivipansel, a pan-selectin antagonist, is being explored as a
potential treatment for acute vaso-occlusive crisis in sickle cell
disease. GlycoMimetics has also completed a Phase 1 clinical trial
with another wholly-owned drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in
Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company’s strategy and the clinical development and potential
utility, benefits and impact of its drug candidates. These
forward-looking statements include those relating to the planned
preclinical research and clinical development of the Company’s
product candidates. Actual results may differ materially from those
expressed in or implied by these forward-looking statements. For a
further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk
factors described in the Company’s annual report on Form 10-K filed
with the U.S. Securities and Exchange Commission (SEC) on February
28, 2020, the updated risk factors described in the Company’s
quarterly report on Form 10-Q filed with the SEC on July 31, 2020,
and other filings GlycoMimetics makes with the SEC from time to
time. Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200831005303/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Feb 2024 to Mar 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2023 to Mar 2024